Case Report

Presumably Corneal Graft Rejection after COVID-19 Vaccination

Maryam Mohammadzadeh\textsuperscript{a} Sadid Hooshmandi\textsuperscript{b} Mina Jafari\textsuperscript{b} Kiana Hassanpour\textsuperscript{b}

\textsuperscript{a}Translational Ophthalmology Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran; \textsuperscript{b}Ophthalmic Research Center, Research Institute for Ophthalmology and Visual Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Keywords
Corneal graft · Graft rejection · COVID-19 · Vaccination

Abstract
We report two cases of corneal graft rejection following immunization with COVID-19-inactivated vaccine Sinopharm and describe the practical implications of this phenomenon in the clinical setting. A 36-year-old woman with a history of unilateral repeated PKP received the first dose of inactivated Sinopharm vaccine. Seven days later, she presented with symptoms and signs of unilateral corneal graft rejection on slit-lamp examination. A 54-year-old woman with a history of unilateral PKP secondary to herpes simplex keratitis (HSK) developed signs of unilateral corneal graft rejection just a week after injection of the first dose of the similar vaccine. Rejection in both patients was treated successfully with topical steroids. To the best of our knowledge, this is the first report of corneal graft rejection following the COVID-19-inactivated Sinopharm vaccine which occurred through the short period after the injection. We hypothesized that the rejection is the result of an allogenic reaction and the immunogenic role of aluminum hydroxide as an adjuvant of this type of vaccine. However, as the second case had a history of rejection following the HSK, a reactivation could not be definitely ruled out. Ophthalmologists should consider these types of adverse reactions after COVID-19 immunization and also monitor a close follow-up of graft health postimmunization. Patients should be informed about the signs and symptoms of rejection, urgent referral, and treatment.
Introduction

Corneal immune privilege is induced both by the lack of blood and lymph vessels in the host tissue and the absence of major histocompatibility complex (MHC) class II antigen-presenting cells (APCs) in the donor tissue. Meanwhile, immunization may induce the presence of this type of cells in all the layers of the cornea and subsequently will increase the chance of rejection in the future [1]. Vaccine-induced corneal graft rejection is a rare phenomenon reported previously with influenza, hepatitis B, yellow fever, and herpes zoster vaccinations [2–5].

There have been few reports of rejection after the corona virus disease-2019 (COVID-19) immunization and with the COVID-19 vaccination rise against SARS-CoV-2 worldwide; we are expecting an increase in the number of rejections. So far research has shown that COVID-19 vaccines are congruent with the increase in specific neutralizing antibodies and CD4+ Th1 cells’ responses against the virus, which are the main responsible cells in the corneal graft rejections [6]. Here, we present 2 patients with corneal endothelial graft rejection after the inactivated Sinopharm COVID-19 vaccination.

Case Presentation

Patient #1

A 36-year-old female presented with a 2-day history of painful red-eye and rapid vision loss in her left eye. She had received the first dose of the inactivated Sinopharm BIBP COVID-19 vaccine just 7 days before the appearance of her symptoms. Her past ocular history included penetrating keratoplasty (PKP) in the left eye approximately 4 years ago for corneal opacity secondary to herpes simplex keratitis (HSK). She had undergone repeated PKP in the left eye due to the failed graft approximately 1 year ago. She was receiving prophylactic oral acyclovir (400 mg bid) after the regraft, topical steroid (fluorometholone every other night), and topical tacrolimus 0.05% (bid). On examination, the best-corrected visual acuity was 20/400 in the left eye using the Snellen chart. Slit-lamp examination (SLE) revealed endothelial and stromal corneal graft rejection in the left eye with the evidence of conjunctival hyperemia, inferior corneal edema, keratic precipitates, and diffuse subepithelial infiltration (Fig. 1a). The right cornea was healthy.

The patient was treated with topical betamethasone every 1 h for 1 day followed by every 2 h up to 7 days with gradual tapering and oral acyclovir 400 mg 5 times a day to cover any possible underlying HSK. Significant improvement was observed 14 days after the treatment, and the signs of inflammation were partially resolved (Fig. 1b).

Patient #2

The second patient was a 54-year-old female who presented with a complaint of ocular discomfort in the left eye 7 days after the first dose of the inactivated Sinopharm BIBP COVID-19 vaccine. She had a history of PKP 2 years prior due to corneal opacity secondary to HSK. The patient was receiving prophylactic oral acyclovir (400 mg bid) and topical tacrolimus (0.05% bid) after the regraft. The best-corrected visual acuity of the left eye was 20/200. The subepithelial opacity and less than 5 keratic precipitates were observed on SLE. Slit-lamp examination (SLE) revealed endothelial and stromal corneal graft rejection in the left eye with the evidence of conjunctival hyperemia, inferior corneal edema, keratic precipitates, and diffuse subepithelial infiltration (Fig. 1a). The right cornea was healthy.

The patient was treated with topical betamethasone every 1 h for 1 day followed by every 2 h up to 7 days with gradual tapering and oral acyclovir 400 mg 5 times a day to cover any possible underlying HSK. Significant improvement was observed 14 days after the treatment, and the signs of inflammation were partially resolved (Fig. 1b).
Discussion

To our knowledge, the number of corneal graft rejections after COVID-19 vaccination is rising [7–17]. Interestingly, we have observed an increasing pattern in corneal graft rejection during the mass vaccination against SARS-CoV-2 in Labbafinejad Medical Center as a referral center in Tehran, Iran.

Eleven cases with acute graft rejection have been reported in the literature. The common features of these patients (summarized in Table 1) include being a regraft in the majority of patients as a risk factor, a short-time interval between two events (mean of 1–2 weeks), and PKP as the most commonly reported transplant type. The most frequent COVID-19 vaccine type reported through literature was mRNA-based and vector-based vaccines BNT162b2 [18] and AZD1222 [19], respectively. However, our report represents two cases of corneal graft rejection following PKP, occurring just a week after the Sinopharm-inactivated COVID-19 vaccine which is the first report after the inactivated-COVID-19 vaccine type so far. The inactivated Sinopharm vaccine developed by Sinopharm (Wuhan, China) is mixed with aluminum hydroxide as an adjuvant, an immunogenic substance and is supposed to be the principal reason for adverse reactions resulting from the vaccine [20, 21].

Rejection of corneal transplant following immunization has previously been reported with other vaccines including influenza [5, 22, 23] and yellow fever [2] which were in association with induction of MHC II APC by immunization. In low risk grafts, the corneal immune
| Study | Age | Sex | Type of graft | Vaccine type | Interval postvaccination (D for days and W for weeks) | Interval postgraft (M for months and Y for years) | Laterality | Risk factor | Treatment | Outcome |
|-------|-----|-----|---------------|--------------|---------------------------------------------------|-------------------------------------------------|-----------|-------------|-----------|---------|
| Abousy et al. [1] | 73 | F | DSAEK | mRNA-based | 2 W after the second dose | 8 Y | Bilateral | None | Topical steroid | Resolved |
| Simão and Kwitko [28] | 63 | F | PKP (x 3) LASIK | Inactivated vaccine (Sinovac) | 1 D after the first dose and the second dose | 4 Y (last PKP) | Unilateral | Regraft | Topical steroid and polydimethylsiloxane | Not resolved |
| Nioi et al. [30] | 44 | F | PKP | mRNA-based | 13 D after the first dose | 25 Y | Unilateral | None | Topical steroids + vitamin D supplement | Resolved |
| Rallis et al. [7] | 68 | F | PKP | mRNA-based | 4 D after the first dose | 4 M | Unilateral | Regraft | Topical steroids | Resolved |
| Ravichandran and Natarajan [8] | 62 | M | PKP | Recombinant vector-based | 3 W after the first dose | 2 Y | Unilateral | None | Topical steroids | Resolved |
| Phylactou et al. [9] Patient #1 | 66 | F | DMEK | mRNA-based | 1 W after the first dose | 3 W | Unilateral | Recency | Topical steroids | Resolved |
| Phylactou et al. [9] Patient #2 | 83 | F | DSAEK | mRNA-based | 3 W after the second dose | 3 Y | Bilateral | Regraft | Topical steroids | Resolved |
| Wasser et al. [10] Patient #1 | 73 | M | PKP | mRNA-based | 2 W after the first dose | 1 Y | Unilateral | Regraft | Topical + systemic steroids | Resolved |
| Wasser et al. [10] Patient #2 | 56 | M | PKP | mRNA-based | 2 W after the first dose | 10 M | Unilateral | Regraft | Topical steroids | Resolved |
| Crnej et al. [11] | 71 | M | DMEK | mRNA-based | 1 W after the first dose | 5 M | Unilateral | None | Topical steroids | Resolved |
| Balidis et al. [12] Patient #1 | 77 | F | DMEK | mRNA-based | 1 W after the first dose | 12 M | Unilateral | Regraft | Topical + systemic steroids | Resolved |
| Balidis et al. [12] Patient #2 | 64 | F | PKP | mRNA-based | 1 W after the second dose | 3 Y | Unilateral | Regraft | Topical + intracameral steroids | Resolved |
| Balidis et al. [12] Patient #3 | 69 | M | PKP | adenoviral vector-based | 5 D after the first dose | 22 M | Unilateral | None | Topical + systemic steroids | Resolved |
| Balidis et al. [12] Patient #4 | 63 | M | DSAEK | adenoviral vector-based | 10 D after the first dose | 9 M | Unilateral | Regraft | Topical steroids | Resolved |
| Study                  | Age | Sex  | Type of graft          | Vaccine type          | Interval postvaccination (D for days and W for weeks) | Interval postgraft (M for months and Y for years) | Laterality | Risk factor | Treatment                                      | Outcome       |
|-----------------------|-----|------|------------------------|-----------------------|--------------------------------------------------------|--------------------------------------------------|------------|-------------|------------------------------------------------|---------------|
| de la Presa et al. [13]| 27  | F    | LR-CLAL (x 2)          | mRNA-based            | 2 W after the first dose                                | 4 Y                                              | Unilateral | Regraft     | Topical steroid and systemic steroid           | Resolved      |
| Parmar et al. [14]    | 35  | M    | PKP                    | adenoviral vector-based | 2 D after the first dose                                | 6 M                                              | Unilateral | Regraft     | Topical and systemic steroid                   | Resolved      |
| Rajagopal and Priyanka [15] | 79  | M    | DSAEK & PKP (x 2)     | vector-based          | 6 W after the second dose                               | 5 Y                                              | Unilateral | Regraft     | Topical and systemic steroid                   | Resolved      |
| Shah et al. [16]      | 74  | M    | DMEK                   | mRNA-based            | 1 W after the first dose                                | 5 M                                              | Unilateral | None        | Topical steroid                               | Resolving     |
| Shah et al. [16]      | 61  | F    | Tectonic then optical PKP and repair | mRNA-based          | 3 W after the first dose                                | 1 Y                                              | Unilateral | Regraft     | Topical steroid                               | Resolving     |
| Shah et al. [16]      | 69  | F    | DSAEK                  | mRNA-based            | 2 W after the second dose                               | 6 Y                                              | Unilateral | DM Salzmann-nodular degeneration              | Resolved      |
| Shah et al. [16]      | 77  | M    | PKP                    | mRNA-based            | 1 W after the second dose                               | 22 Y                                             | Unilateral | None        | Topical steroid                               | Resolved      |
| Yu et al. [17]        | 51  | M    | PKP                    | SARS-CoV-2 mRNA-1273 Moderna vaccine             | 3 D after the first dose                            | 3 W                                              | Unilateral | Regraft     | Topical steroid                               | Not resolved  |

PKP, penetrating keratoplasty; DSAEK, descemet stripping automated endothelial keratoplasty; DMEK, descemet membrane endothelial keratoplasty; LASIK, laser-assisted in situ keratomileusis. DM, diabetes mellitus.
The privilege could prevent the rejection episodes. This phenomenon explains the low rate of rejection after COVID-19 vaccination. Moreover, previous research has shown that corneal regraft can increase the risk of rejection, especially after the history of 2 or more past rejections [24]. The disruption in the mechanisms of anterior chamber-associated immune deviation and alterations in the function of APCs are responsible for higher episodes of graft rejection in patients undergoing the second keratoplasty [25]. When the disruption in immune privilege occurs, the rejection episode could be observed as early as 1 week like in our patient. The breakdown could be attributed to the presence of corneal vascularization or MHC II acting as APCs for the immune recognition of corneal donor [25].

To date, different types of COVID-19 vaccines have been used worldwide with 3 main mechanisms of action: 1. protein-based vaccines like the inactivated China’s COVID-19 vaccines Sinovac and Sinopharm make up the viral protein in vitro; 2. gene-based vaccines like DNA or mRNA-based vaccines such as BNT162b2, Pfizer-BioNTech, and mRNA-1273, Moderna deliver the gene encoding a viral protein; or 3 combination of both [26, 27]. Simao and colleagues reported the rejection episode after an inactivated vaccine (Sinovac Biotech, Beijing, China) [28]. The patient had signs of endothelial graft rejection and fluid accumulation in the interface 24 h after vaccination. To the best of our knowledge, this is the first report of corneal graft rejection following the COVID-19-inactivated Sinopharm vaccine which occurred through the short period after the injection.

It is well known that the mRNA-based vaccines strongly trigger both humoral and cellular immunity which leads to an increase in SARS-CoV-2-neutralizing antibodies, antigen-specific Th1-CD4+ responses, and an increase in proinflammatory cytokines such as interferon-gamma which play a key role in allograft rejection [6]. However, the pathogenesis of graft rejection following inactivated vaccines such as Sinopharm is not yet known.

Although the causality between COVID-19 immunization and corneal graft rejection cannot be concluded from this study, the temporal association between these two events reported in our cases and through the literature might confirm the hypothesis that the immune system upregulation induced by vaccination might be responsible for this phenomenon. Moreover, Nioi et al. [29, 30] reported a similar case and used the causality assessment of an adverse event following immunization guidelines to perfectly demonstrate this relationship.

There have been few reports about the adverse effects of COVID-19 vaccination on ocular HSV and VZV reactivation such as herpes zoster ophthalmicus [31, 32], granulomatous uveitis [30], keratouveitis glaucoma [33], and herpetic keratitis. Richardson-May et al. [34] reported the first case of HSK reactivation following the COVID-19 vaccination (AstraZeneca vaccine) in an 82-year-old male with a history of previous HSK. SLE revealed reduced corneal sensation and typical dendritic lesions. Furthermore, Alkwikbi et al. [33] reported 4 cases of HSK reactivation after COVID-19 vaccination (AstraZeneca and Pfizer-BioNTech vaccine) each with typical HSK dendritic epithelial ulcers, and Song et al. [35] reported a relapsed case of disciform stromal herpetic keratitis after the Pfizer-BioNTech vaccine with typical round stromal infiltration.

However, HSK reactivation postvaccination in patients with a history of corneal grafts has been rarely reported in the literature. Li et al. [36] reported two cases of HSK reactivation following COVID-19 vaccination (Sinopharm vaccine) with a history of PKP in one of the patients. On SLE, there was a typical HSV dendritic lesion in the center of the graft. The diagnosis of recurrent herpes simplex epithelial keratitis was confirmed with PCR of lesion scrapings [36].

Both of our patients underwent PKP due to HSK. The recurrence of HSK is among the differential diagnoses with a strong possibility. However, the presence of edema in the recipient bed in the first patient is in favor of corneal graft rejection. Moreover, the lack of corneal edema in the second patient reduces the possibility of HSV infection. Due to the difficulty in exact diagnoses, both rejection and recurrence of HSV keratitis were simultaneously treated.
Although there are an increasing number of case reports supporting this hypothesis, future studies especially with high-level evidence are needed to completely demonstrate this relationship. We acknowledge that clinical observations are prone to various biases, but we believe that ophthalmologists and general practitioners should be aware of this potential risk associated with the vaccination, and patients should be counseled on the early symptom and signs of rejection.

We also recommend COVID-19 vaccine administration ahead of time for nonurgent keratoplasties and using topical betamethasone every 6 h at least 3 days before immunization. In patients with a history of HSK as the indication of keratoplasty, prophylaxis with systemic acyclovir is also recommended just before receiving COVID-19 vaccination for a 2-week duration.

Statement of Ethics

Written informed consent was obtained from the patients for publication of the details of their medical case and any accompanying images. Ethical approval is not required for this study in accordance with local or national guidelines.

Conflict of Interest Statement

The authors declare no conflict of interest.

Funding Sources

The authors received no funding for this report.

Author Contributions

Kiana Hassanpour, senior author, did the data gathering and edited the final version. Maryam Mohammadzedeh and Mina Jafari performed the literature review and helped in drafting the manuscript. Sadid Hooshmandi took the photos and helped in writing the draft. All authors read and approved the final version to submit.

Data Availability Statement

All data generated and analyzed during this study are included in this article. Further inquiries can be directed to the corresponding author.

References

1. Abousy M, Bohm K, Prescott C, Bonsack JM, Rowhani-Farid A, Eghrari AO, et al. Bilateral EK rejection after COVID-19 vaccine. *Eye Contact Lens.* 2021;47(11):625–8.
2. Vignapiano R, Vicchio L, Favuzza E, Cennamo M, Mencucci R. Corneal graft rejection after yellow fever vaccine: a case report. *Ocular Immunol Inflamn.* 2021;1–4.
3. Matoba A. Corneal allograft rejection associated with herpes zoster recombinant adjuvanted vaccine. *Cornea.* 2021;41(6):772–4.
4 Steinemann TL, Koffler BH, Jennings CD. Corneal allograft rejection following immunization. Am J Ophthalmol. 1988;106(5):575–8.
5 Wertheim MS, Keel M, Cook SD, Tole DM. Corneal transplant rejection following influenza vaccination. Br J Ophthalmol. 2006;90(7):925.
6 Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. MedRxiv. 2020.
7 Rallis KI, Ting DSJ, Said DG, Dua HS. Corneal graft rejection following COVID-19 vaccine. Eye. 2021;36(6):1319–20.
8 Ravichandran S, Natarajan R. Corneal graft rejection after COVID-19 vaccination. Indian J Ophthalmol. 2021;69(7):1953.
9 Phyliactou M, Li J-P, Larkin DFP. Characteristics of endothelial corneal transplant rejection following immunisation with SARS-CoV-2 messenger RNA vaccine. Br J Ophthalmol. 2021;105(7):893–6.
10 Wasser LM, Roditi E, Zadok D, Berkowitz L, Weill Y. Keratoplasty rejection after the BNT162b2 messenger RNA vaccine. Cornea. 2021;40(8):1070–2.
11 Crneje A, Khoueir Z, Chena F, Saad A. Acute corneal endothelial graft rejection following COVID-19 vaccination. J Francais D’Ophthalmologie. 2021;44(8):e445–e447.
12 Balidis M, Mikropoulos D, Gatziosfas Z, de Politis PB, Sidipoulos G, Vassiladias V, et al. Acute corneal graft rejection after anti-severe acute respiratory syndrome coronavirus-2 vaccination: a report of four cases. Eur J Ophthalmol. 2021;112067211210643.
13 de la Presa M, Govil A, Chamberlain WD, Holland EJ. Acute corneal epithelial rejection of LR-CLAL after SARS-CoV-2 vaccination. Cornea. 2022;41(2):252–3.
14 Parmer DP, Garde PV, Shah SM, Bhole PK. Acute graft rejection in a high-risk corneal transplant following COVID-19 vaccination: a case report. Indian J Ophthalmol. 2021;69(12):3757.
15 Rajagopal R, Priyanka TM. Stromal rejection in penetrating keratoplasty following COVID-19 vector vaccine (Covivishield): a case report and review of literature. Indian J Ophthalmol. 2022;70(1):319.
16 Shah AP, Dhaher B, Kenyon KR, Riaz KM, Ouano D, Koo EH, et al. Acute corneal transplant rejection after COVID-19 vaccination. Cornea. 2022;41(1):121–4.
17 Yu S, Ritterband DC, Mehta L. Acute corneal transplant rejection after severe acute respiratory syndrome coronavirus-2 mRNA-1273 vaccination. Cornea. 2022;41(2):257–9.
18 World Health Organization. The Pfizer BioNTech (BNT162b2) COVID-19 vaccine: what you need to know; 2021.
19 AstraZeneca. AZD1221 vaccine met primary efficacy endpoint in preventing COVID-19; 2020.
20 Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51.
21 Ng XL, Betzler BK, Ng S, Chee SP, Rajamani L, Singhal A, et al. The eye of the storm: COVID-19 vaccination and the eye. Ophthalmol Ther. 2021;11:81–100.
22 Hamilton A, Massera R, Malloof A. Stromal rejection in a deep anterior lamellar keratoplasty following influenza vaccination. Clin Exp Ophthalmol. 2015;43(9):838–9.
23 Solomon A, Frucht-Pery J. Bilateral simultaneous corneal graft rejection after influenza vaccination. Am J Ophthalmol. 1996;121(6):709–9.
24 Di Zazzo A, Kheirkhah A, Abud TB, Goyal S, Dana R. Management of high-risk corneal transplantation. Surv Ophthalmol. 2017;62(6):816–27.
25 Streilein JW. Unraveling immune privilege. Science. 1995;270(5239):1158.
26 Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021;21(2):73–82.
27 Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines: a new era in vaccination. Nat Rev Drug Discov. 2018;17(4):261–79.
28 Simão MF, Kwitko S. Corneal graft rejection after inactivated SARS-CoV-2 vaccine: case report. Cornea. 2022;41(4):502–4.
29 World Health Organisation. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification; 2018.
30 Niai M, d’Alloja E, Fossarello M, Napoli PE. Dual corneal-graft rejection after mrna vaccine (Bnt162b2) for covid-19 during the first six months of follow-up: report of the case. Indian J Ophthalmol. 2021;69(11):1274.
31 Herbort CP, Papasavvas I. Effect of SARS-CoV-2 mRNA vaccination on ocular herpes simplex and varicella-zoster virus reactivation: should preventive antiviral treatment be given in known herpes patients. J Ophthalmic Inflamm Infect. 2021;11(1):33.
32 Eid E, Abdullah L, Kurban M, Abbas O. Herpes zoster emergence following mRNA COVID-19 vaccine. J Med Virol. 2021;93(9):5231–2.
33 Alkwwibi H, Alenazi M, Alnazi M, Alruwaili S. Herpetic keratitis and corneal endothelitis following COVID-19 vaccination: a case series. Cureus. 2022;14(1):e20967.
34 Richardson-May J, Rothwell A, Rashid M. Reactivation of herpes simplex keratitis following vaccination for COVID-19. BMJ Case Rep CP. 2021;14(9):e245792.
35 Song MY, Koh KM, Hwang KY, Kwon YA, Kim KY. Relapsed disciform stromal herpetic keratitis following mRNA COVID-19 vaccination: a case report. Korean J Ophthalmol KJO. 2022;36(1):80–2.
36 Li S, Jia X, Yu F, Wang Q, Zhang T, Yuan J, et al. Herpetic keratitis preceded by COVID-19 vaccination. Vaccines. 2021;9(12):1394.